Post-earnings recap
Reported
Wed, Aug 5, 2026
EPS actual
$0.11
EPS est.
$0.09
EPS surprise
+29.41%
1-day move
+4.11%
Arcutis Biotherapeutics reported a positive surprise in EPS, which contributed to a 4.11% increase in stock price. However, there was no revenue reported, leaving some uncertainty about overall performance. Investors may be encouraged by the EPS beat, but the lack of additional context from management could lead to cautious sentiment moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.11 | N/A | +29.41% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.
Arcutis Biotherapeutics, Inc. (ARQT) is a biotechnology company focused on developing innovative treatments for skin diseases. With a market cap of $3 billion, it plays a significant role in the health care sector, particularly in dermatology, which is seeing increasing demand for effective therapies.
Last quarter
In Q1 2026, Arcutis reported an EPS of -$0.09, which was significantly below the expected -$0.02, resulting in a 3.20% increase in stock price the following day. The company has shown a strong track record of beating EPS estimates in previous quarters.
EPS beat streak
1Q
EPS beat rate
88%
Avg EPS surprise
+21.79%
Avg 1-day reaction
+3.74%
Overall expectations for Arcutis are mixed, given the company's recent performance and lack of analyst estimates. Investors will be looking for signs of recovery in profitability and revenue growth.
Bull case
If Arcutis can demonstrate strong revenue growth and continued progress in its product pipeline, it could lead to a significant increase in stock price, reflecting investor confidence.
Bear case
On the other hand, if the company fails to meet expectations for revenue or shows setbacks in its product development, it could lead to a decline in stock price, especially given the recent EPS miss.
The print will turn on these.
Q1
What is the expected revenue growth for the upcoming quarter?
Revenue growth is crucial for assessing the company's market performance and future profitability, especially after last quarter's EPS miss.
Q2
What updates can management provide on the product pipeline?
Insights into the product pipeline can significantly influence investor sentiment and expectations for future revenue.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may be underestimating the potential for Arcutis to rebound with strong product pipeline updates, which could drive significant revenue growth despite recent misses.
Supporting evidence
The company's historical EPS beat rate of 88% suggests a strong potential for positive surprises.
Options pricing indicates a high expected move, suggesting traders anticipate volatility that could favor a rebound.
Recent stock price movements show resilience despite earnings misses, indicating underlying strength.
Key risk
If revenue growth exceeds expectations, it could significantly alter the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as it will indicate whether Arcutis can regain momentum after recent earnings misses.
Bull confirmed if
Demonstrating revenue growth of over 15% compared to the previous quarter would confirm the bull case.
Bear confirmed if
If revenue growth is flat or negative, it would support the bear case.
What the market is pricing for the move.
Implied Move
±18.36%
Historical Avg
±5.9%
The options market is pricing in a significant move of over 18%, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±18.4% while ARQT has averaged ±5.9% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
62.0%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
108.73%
of float
Insider
1.77%
of float
Holders
387
institutions
Top Holders· as of Jun 2026
Montanova Capital LLC
12,437,000 sh · $300.6M
9.89%
0.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Arcutis beats expectations, history suggests the stock could rise by an average of 2.7%, confirming a positive outlook.
In line / cautious
If results are in line but management is cautious, the stock may experience a muted reaction as investors reassess their expectations.
Miss
Should the company miss expectations, history suggests a potential decline of around 3.2%, reflecting investor disappointment.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Blackrock Inc.
10,545,466 sh · $254.9M
8.39%
14.6%
Frazier Life Sciences Management, L.P.
9,874,511 sh · $238.7M
7.86%
Flat
Rubric Capital Management LP
8,271,577 sh · $199.9M
6.58%
Flat
Polar Capital Holdings PLC
6,606,945 sh · $159.7M
5.26%
16.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded May 29, 2026 · disclosed Jun 8, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.